Company Description
Bio Essence (OTC Link: BIOE) is a publicly traded drug manufacturers - specialty & generic company in the Healthcare sector. The company has a market capitalization of $5.7M.
BIOE stock has declined 29.9% over the past year. Shares last traded at $0.1500.
On a trailing twelve-month basis, Bio Essence reported revenue of $1.9M with net income of $896K and diluted earnings per share of $0.02. The company operates at a net profit margin of 47.2%.
This page provides a comprehensive overview of BIOE stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Bio Essence (BIOE) stock last traded at $0.1500, up 23.07% from the previous close. Over the past 12 months, the stock has lost 29.9%. At a market capitalization of $5.7M, BIOE is classified as a micro-cap stock with approximately 38.0M shares outstanding.
Latest News
Bio Essence has 2 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 0 with negative movement. Key topics include offering. View all BIOE news →
SEC Filings
Bio Essence has filed 2 recent SEC filings, including 1 Form 10-K, 1 Form 10-Q. The most recent filing was submitted on March 27, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all BIOE SEC filings →
Financial Highlights
Bio Essence generated $1.9M in revenue over the trailing twelve months, retaining a 75.3% gross margin, operating income reached $900K (47.4% operating margin), and net income was $896K, reflecting a 47.2% net profit margin. Diluted earnings per share stood at $0.02. The company generated $1.6M in operating cash flow.
Upcoming Events
Short Interest History
Days to Cover History
BIOE Company Profile & Sector Positioning
Bio Essence (BIOE) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the OTC Link.